首页> 外国专利> Formulation of sustained Release Tablets of piperazine piperidine antagonists and agonists of the receptor - 5 at the 5-ht1a Aripiprazole with improved Dissolution instestinal

Formulation of sustained Release Tablets of piperazine piperidine antagonists and agonists of the receptor - 5 at the 5-ht1a Aripiprazole with improved Dissolution instestinal

机译:在5-ht1a阿立哌唑上配制哌嗪哌啶拮抗剂和受体激动剂-5的缓释片,改善肠溶度

摘要

The sustained release pill formula of methyldiazepine can be used for the treatment of central nervous system disorders: a preparation process, as well as the method of use. Requirement 1: a sustained release pill formula for oral characteristics Because it includes: (a) a formula compound (1),or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, and R16, are each independently -H, alkyl- (C1-6),1. Halide (C1-6),alquenilo- (C2-6)Or tar (c2-6)Halocarbon, CF3, NO2, CN, or25, SO2, R25, sr25, so2r25, so2n (R25) 2, n (R25) 2, C (o),-Cor25, co2r25, nr25co2r25, nr25cor25, nr25con (R25) 2, o-con (R25) 2RA and Rb are respectively h-o-ch3; R25 es-h, acquilo - (C1-6) direct or branch, haloguilo - (C1-6) alquenilo - (c2-6),Or bitumen - (c2-6);(b) at least one organic acid; (c) at least one release controller; (d) at least one filler; and (e) at least one lubricant. Claim 4: The formulation of any one of claims 1 to 3, characterized in that the compound of formula (1) is selected from the group consisting of: 6-methoxy-8- [4- (1-quinolin-8-yl -piperidin-4-yl) -piperazin-1-yl] -quinoline; 6-fluoro-8- [4- (1-quinolin-8-yl-piperidin-4-yl) -piperazin-1-yl] -quinoline; 5-fluoro-8- [4- (1-quinolin-8-yl-piperidin-4-yl) -piperazin-1-yl] -quinoline; 7-fluoro-8- (4- (4- (6-methoxyquinolin-8-yl) piperazin-1- yl) piperidin-1-yl) quinoline;6-fluoro-8- {4- [1- (8-fluoroquinolin-7-yl) piperidin-4-yl] piperazin-1-yl) quinoline; 3-trifluoromethyl-8- (4- (4- (6-methoxyquinolin-8-yl) piperazin-1-yl) piperidin-1-yl) quinoline; 6-methoxy-8- (4- (1- (quinolin-8-ylmethyl) piperidin-4-yl) piperazin-1-yl) quinoline; 5-fluoro-4-methoxy-8- (4- (4- (6-methoxyquinolin-8-yl) piperazin-1-yl) piperidin-1-yl) -2- (trifluoromethyl) quinoline; 5-fluoro-8- (4- (4- (6-methoxyquinolin-8-yl) piperazin-1-yl) piperidin-1-yl) quinoline; 5-Fluoro-8- (4- (4- (6-methoxyquinolin-8-yl) piperazin-1-yl) piperidin-1-yl) quinoline trisuccinate; 8- [4- (1-quinolin-8-yl-piperidin-4-yl) -piperazin-1-jl] -quinoline; 6-chloro-8- [4- (4- (6-chloro) -quinolin-8-yl-piperidin-1-yl) -piperazin-1-yl] -quinoline;6-fluoro-8- [4- (4- (6-chloro) -quinolin-8-yl-piperidin-1-jl) -piperazin-1-yl] -quinoline; 5-chloro-8- [4- (1-quinolin-8-yl-piperidin-4-yl) -piperazin-1-yl] -quinoline; 2-methyl-8- [4- (1-quinolin-8-yl-piperidin-4-yl) -piperazin-1-yl] -quinoline; 6-chloro-8- [4- (1-quinolin-8-yl-piperidin-4-yl) -piperazin-1-yl] -quinoline; 8- [4- (1-quinolin-8-yl-piperidin-4-yl) -pjperazin-1-yl] -5-trifluoromethyl-quinoline; 5-methoxy-8- [4- (1-quinolin-8-yl-piperidin-4-yl) -piperazin-1-yl] -quinoline; 5-fluoro-8- [4- (4-quinolin-8-yl-piperazin-1-yl) piperidin-1-yl] -quinoline; 6-methoxy-8- [4- (2-methylquinolin-8-yl-piperidin-4-yl) -piperazin-1-yl] -quinoline; 6-fluoro-8- (4- (1- (2-methylquinolin-8-yl) piperidin-4-yl) piperazin-1-yl) quinoline;- 1-1-1-1 - (1-1 -) (1-1 -) (1 (1 - (2,4-dimethyl-5-fluoroquinol-8-il) piperidin-4-il) piperazin-1-il; 2. Handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle handle;6-fluoro-8- (4- (1- (7-fluoroquinolin-8-yl) piperidin-4-yl) piperazin-1-yl) quinoline; 6-methoxy-8- {4- [1- (8-fluoroquinolin-7-yl) piperidin-4-yl] piperazin-yl} quinoline; 6-methoxy-8- {4- [1- (2-trifluoromethyl-4-methoxyquinolin-7-yl) piperidin-4-yl] piperazin-1-yl} quinoline; 6-methoxy-8- (4- (1- (2-trifluoromethyl-4-methoxyquinolin-8-yl) piperidin-4-yl) piperazin-1-yl) quinoline; 5-fluoro-8- (4- (4- (6-methoxyquinolin-8-yl) piperazin-1-yl) piperidin-1-yl) -2-trifluoromethylquinoline; 5-fluoro-8- (4- (4- (6-methoxyquinolin-8-yl) piperazin-1-yl) piperidin-1-yl) -3-trifluoromethylquinoline; 5-fluoro-8- (4- (4- (6-methoxyquinolin-8-yl) piperazin-1-yl) piperidin-1-yl) -4-trifluoromethylquinoline;1 - (6-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1 yes
机译:甲基二氮杂的缓释药配方可用于治疗中枢神经系统疾病:其制备方法以及使用方法。要求1:口服特性的缓释药配方,因为它包括:(a)配方化合物(1)或其药学上可接受的盐,其中R1,R2,R3,R4,R5,R6,R7,R8,R9 R 10,R 11,R 12,R 13,R 14,R 15和R 16各自独立地为-H,烷基-(C 1-6),1。卤化物(C1-6),alquenilo-(C2-6)或焦油(c2-6)卤代烃,CF3,NO2,CN或or25,SO2,R25,sr25,so2r25,so2n(R25)2,n(R25)2 C(o),-Cor25,co2r25,nr25co2r25,nr25cor25,nr25con(R25)2,o-con(R25)2RA和Rb分别为ho-ch3; R 25 es-h,acquilo-(C1-6)直链或支链,haloguilo-(C1-6)烷基-(c2-6),或沥青-(c2-6);(b)至少一种有机酸; (c)至少一个释放控制器; (d)至少一种填料; (e)至少一种润滑剂。权利要求4:权利要求1-3中任一项的制剂,其特征在于式(1)的化合物选自:6-甲氧基-8- [4-(1-喹啉-8-基-哌啶-4-基)-哌嗪-1-基]-喹啉; 6-氟-8- [4-(1-喹啉-8-基哌啶-4-基)-哌嗪-1-基]-喹啉; 5-氟-8- [4-(1-喹啉-8-基-哌啶-4-基)-哌嗪-1-基]-喹啉; 7-氟-8-(4-(4-(6-甲氧基喹啉-8-基)哌嗪-1-基)哌啶-1-基)喹啉; 6-氟-8- {4- [1-(8-氟喹啉-7-基)哌啶-4-基]哌嗪-1-基)喹啉; 3-三氟甲基-8-(4-(4-(6-甲氧基喹啉-8-基)哌嗪-1-基)哌啶-1-基)喹啉; 6-甲氧基-8-(4-(1-(1-喹啉-8-甲基)哌啶-4-基)哌嗪-1-基)喹啉; 5-氟-4-甲氧基-8-(4-(4-(6-甲氧基喹啉-8-基)哌嗪-1-基)哌啶-1-基)-2-(三氟甲基)喹啉; 5-氟-8-(4-(4-(6-甲氧基喹啉-8-基)哌嗪-1-基)哌啶-1-基)喹啉; 5-氟-8-(4-(4-(6-甲氧基喹啉-8-基)哌嗪-1-基)哌啶-1-基)喹啉三琥珀酸酯; 8- [4-(1-喹啉-8-基哌啶-4-基)-哌嗪-1-jl]-喹啉; 6-氯-8- [4-(4-(6-氯)-喹啉-8-基-哌啶-1-基)-哌嗪-1-基]-喹啉; 6-氟-8- [4-( 4-(6-氯)-喹啉-8-基-哌啶-1-基]-哌嗪-1-基]-喹啉; 5-氯-8- [4-(1-喹啉-8-基-哌啶-4-基)-哌嗪-1-基]-喹啉; 2-甲基-8- [4-(1-喹啉-8-基哌啶-4-基)-哌嗪-1-基]-喹啉; 6-氯-8- [4-(1-喹啉-8-基哌啶-4-基)-哌嗪-1-基]-喹啉; 8- [4-(1-喹啉-8-基哌啶-4-基)-哌嗪-1-基] -5-三氟甲基喹啉; 5-甲氧基-8- [4-(1-喹啉-8-基哌啶-4-基)-哌嗪-1-基]-喹啉; 5-氟-8- [4-(4-喹啉-8-基哌嗪-1-基)哌啶-1-基]-喹啉; 6-甲氧基-8- [4-(2-甲基喹啉-8-基哌啶-4-基)-哌嗪-1-基]-喹啉; 6-氟-8-(4-(1-(2-甲基喹啉-8-基)哌啶-4-基)哌嗪-1-基)喹啉;-1-1-1-1-(1-1-) (1-1-)(1(1-(1,(2,4-二甲基-5-氟喹啉-8-il)哌啶-4-il)哌嗪-1-il; 2.手柄手柄手柄手柄手柄手柄手柄手柄手柄手柄手柄手柄手柄手柄手柄手柄手柄手柄手柄手柄手柄手柄手柄手柄手柄手柄手柄手柄手柄手柄手柄手柄手柄手柄手柄手柄手柄手柄手柄手柄手柄手柄手柄手柄手柄手柄手柄手柄手柄手柄手柄手柄手柄手柄手柄手柄手柄手柄手柄手柄手柄手柄手柄; 6-f luoro-8-(4-(1-(1-(7-氟喹啉-8-基)哌啶-4-基)哌嗪-1-基)喹啉; 6-甲氧基-8- {4- [1-(8-氟喹啉-7-基)哌啶-4-基]哌嗪基}喹啉; 6-甲氧基-8- {4- [1-(2-(2-三氟甲基-4-甲氧基喹啉-7-基)哌啶-4-基]哌嗪-1-基}喹啉; 6-甲氧基-8-(4-(1-(2-(2-三氟甲基-4-甲氧基喹啉-8-基)哌啶-4-基)哌嗪-1-基)喹啉; 5-氟-8-(4-(4-(6-甲氧基喹啉-8-基)哌嗪-1-基)哌啶-1-基)-2-三氟甲基喹啉; 5-氟-8-(4-(4-(6-甲氧基喹啉-8-基)哌嗪-1-基)哌啶-1-基)-3-三氟甲基喹啉; 5-氟-8-(4-(4-(6-甲氧基喹啉-8-基)哌嗪-1-基)哌啶-1-基)-4-三氟甲基喹啉; 1-(6-1-1-1-1 -1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1是

著录项

  • 公开/公告号AR065376A1

    专利类型

  • 公开/公告日2009-06-03

    原文格式PDF

  • 申请/专利权人 WYETH HOLDINGS CORPORATION;

    申请/专利号AR2008P100662

  • 发明设计人

    申请日2008-02-15

  • 分类号A61K31/496;A61K9/22;A61P25/16;A61P25/18;A61P25/28;A61P25/30;

  • 国家 AR

  • 入库时间 2022-08-21 19:28:39

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号